Compare Neurocrine Biosciences Inc (NBIX) vs Oracle Corporation (ORCL) Price & Performance

Neurocrine Biosciences IncTrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Oracle Corporation — how do they compare? Neurocrine Biosciences Inc trades at $158.2 (market cap $16.46B), while Oracle Corporation trades at $149.75 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 25.5× Neurocrine Biosciences Inc's market cap, and Oracle Corporation pays a 1.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	NBIX	ORCL
Market Cap	$16.46B	$419.05B
Sector	Health	Technology
52-Week High	$185.50	$328.33
52-Week Low	$123.10	$114.99
Enterprise Value	$16.48B	$548.30B
Dividend Yield	—	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Oracle Corporation

Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.

Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 5 hours agoBullish View details →

ORCL

Microsoft shares rise after strong Q4, with $604 price target and 20% upside forecast.24/7 Wall Street · 4 hours agoBullish Nebius shares jump 3.7% as NVIDIA backs $500B AI cloud fund, Oracle slips amid competitive pressure.24/7 Wall Street · 22 hours agoBullish Oracle poised for 40% gain as AI cloud growth and backlog surge drive bullish outlook24/7 Wall Street · 1 day agoBullish View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.